Loading...
XSWX
SANN
Market cap229mUSD
Oct 09, Last price  
14.28CHF
1D
0.99%
1Q
-6.18%
Jan 2017
-97.31%
IPO
-98.46%
Name

Santhera Pharmaceuticals Holding AG

Chart & performance

D1W1MN
XSWX:SANN chart
P/E
—
P/S
2.41
EPS
—
Div yield, %
—
Shrs. gr., 5y
57.77%
Rev. gr., 5y
38.75%
Revenues
77m
+97.32%
781,0009,226,00048,0001,643,00020,609,0003,265,0003,538,0001,319,0002,591,0004,321,00019,033,00022,943,00031,657,00075,376,00015,008,000-1,595,0007,473,000103,414,00039,117,00077,185,000
Net income
-49m
L+17.30%
-28,258,000-27,871,000-44,656,00025,923,000-11,256,000-27,838,000-31,448,000-5,755,000-7,534,0005,949,000-35,415,000-51,532,000-54,186,000-18,973,000-67,659,000-55,526,000-71,076,00054,782,000-41,974,000-49,236,000
CFO
-35m
L-2.15%
-24,833,000-22,371,000-45,691,000-20,753,000-6,636,000-19,894,000-11,039,000-6,976,000-6,063,000-22,390,000-27,137,000-39,633,000-37,865,0002,595,000-43,510,000-37,359,000-29,843,00047,271,000-35,527,000-34,763,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.

Related entities

Subsidiaries
SANTHERA PHARMACEUTICALS (SWITZERLAND) LTD

Key people

Elmar J. Schnee
Chairman of the Board
Dario Eklund
Chief Executive Officer, Director · since 2019
Guenther Metz
Senior Vice President Business Development, Member of the Executive Management Board · since 2015
Todd M. Bazemore
Chief Operating Officer Santhera U.S., Member of the Executive Management Board · since 2016
Kristina Nygren
Chief Medical Officer and Head of Development, Member of the Executive Management Board · since 2017
Giovanni Stropoli
Chief Commercial Officer Europe & Rest of World, Member of the Executive Management Board · since 2015
Philipp Gutzwiller
Director · since 2017
Patrick Vink
Director · since 2017
URL
https://www.santhera.com/
IPO date
Nov 03, 2006
Employees
45
Domiciled in
CH
Incorporated in
CH
Headquarters & legal address
HOHENRAINSTRASSE 24
PRATTELN, BL 4133
CH
Previous name
MyoContract AG
Previous name
MyoContract Pharmaceutical Research AG
Previous name
Santhera Pharmaceuticals AG

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT